cdkn2a and tp53 mutation in hpv-negative hnscc
Published 4 years ago • 835 plays • Length 4:11Download video MP4
Download video MP3
Similar videos
-
2:21
correlation of tmb with cdkn2a and tp53 mutation in hpv-negative hnscc
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
1:21
what is the future of hpv-positive and hpv-negative head and neck cancer management?
-
1:40
anti-pd-l1/tgf-β trap in non-hpv associated hnscc
-
0:46
the prognostic impact of tp53 mutation in mpns
-
3:34
p53 tumour suppressor and mdm2
-
0:41
p53 in colon cancer
-
1:15
clinical impact of atm and tp53 mutations in mantle cell lymphoma
-
1:54
does tp53-mutated clonal size impact outcomes of cll patients from the murano study?
-
0:58
immunotherapy and cancer vaccines in anal squamous cell carcinoma
-
0:37
cdk4/6 inhibitors in her2-negative breast cancer based on phase iii monaleesa-7 trial
-
3:51
the origins of ovarian cancer: from tp53 to stic lesions
-
1:29
the potential for immunotherapy in her2 breast cancer
-
0:58
kidney cancer scan types | national kidney foundation
-
10:54
metastatic gastric cancer: indications and impact of angiogenesis inhibitors
-
2:39
metastatic pancreas cancer: beyond second-line treatment
-
8:55
cdk4/6 inhibitors in hr metastatic breast cancer
-
1:30
dr. von minckwitz on phase iii results of the aphinity trial for breast cancer
-
4:45
cdk4/6 inhibitors for hr metastatic breast cancer